Halfway Home Pets

Lets' get them the life they need

Oncotarget is an international peer-reviewed journal that delves mainly on cancer treatment, therapy areas, and the various treatment protocols used in enhancing the lives of cancer patients. Furthermore, the journal looks on the effects of the different cancer management programs and emerging treatments and how they influence the outcomes. In addition, the issues surrounding embracement of such therapies by both the patients and the healthcare providers are discussed.

RG Impact History

Research Gate uses data collected from the number of times articles published in a given journal are cited. In 2010, the RG Journal impact of Oncotarget was 0.19. In 2011, those figures increased to 1.69 meaning that every article published in this journal was cited at least 1.69 times. The figure rose to 2.90 in 2012 and reduced slightly in 2013 to 2.85. The best year for Oncotarget was 2004, when the average number of times any work published in the journal was cited hit 3.69 times. In the 2015/2016 period, the journal’s impact stood at 0.28 points lower than 2014.

Oncotarget to Start Publishing Issues Per Week

On September 19, 2017, Oncotarget reassured its readers about the availability of its scientific publications in places such as the PubMed Central, ISI/Web of Science, and Biological Abstracts among others. The company is working hard to ensure that it becomes the first research journal present a whole issue to PubMed within days after online publication.The journal works with prominent scientific indexes and archives to enhance the availability and accessibility of scientific findings to medical researchers and the general public. The company has now considered increasing the number of weekly issues to two to enhance the indexing process. In addition to oncology, the journal also publishes sub-sections touching on aging, immunology, and microbiology among others. So far, they have posted seven volumes since 2010 and are now publishing the eighth one. According to the journals Office of External and Legal Affairs, they are determined to face the challenges of the 21st century, and that’s why they are working around the clock to become known for making scientific findings rapidly available. As a journal by scientists for scientists, Oncotarget will act as a resource for scientists around the world in their effort to fight and end diseases.

Cameron Clokie is known to be a doctor by profession; he practices oral surgeon and also works as a professor of oral, plus maxillofacial surgery at the U of T (University of Toronto). As a surgeon, he is a specialist in oral as well as maxillofacial surgery.

According to Crunchbase, Cameron Clokie gained his education from several institutions which made him acquire more experience in the field of medicine. Also, he is working as a lecturer, and through teaching, he encounters some challenges which usually need more research and through that, he increases his knowledge.

During his studies, he achieved his title as a DDS (Doctor of Dental Surgeon) in the year 1985. Later, as he had a passion for becoming the best surgeon, he continued to specialize in that field, and in the year 1990, he finished his studies which later upgraded his specialization and earned him a doctorate, which was in the year 1992 from the University of McGill.

Dr.Cameron is a well-known leader, an established and experienced surgeon and he has been the Induce Biologics Inc. CEO, which is a company focused on the innovative solutions for the bones reconstruction. Over the decades, Cameron has been involved in the academics where he lectures on dental care as well as clinical practice.

Bloomberg has it that Cameron was named as the head of Oral and Maxillofacial surgery in the year 1998, and later he became the professor of Oral and Maxillofacial surgery at the U of T until the year 2017 when he retired from academics.

He also used to advise several companies on matters related to medics. Through his academics, he has published many papers where he made several presentations in locally as well as internationally, specifically on bones reconstruction as well as medicine regenerative.

Dr. Cameron has more than 25 US plus other pending patents which include the bone healing procedures. Also, he has ventured into many business activities which have made him recognized within and internationally. Cameron uses this platform to extend his knowledge to various places and help many people change their lives through the innovation as well as technology like that of jaw transformation.

Co-founded by Mark Okada and James Dondero in 1993, Highland Capital is one of the country’s largest global venture capitalist firms. The business is independently owned and has more than 200 employees. It is focused on applying credit strategies for managing alternative investments that include, hedge funds, mutual funds, separate accounts, equity, fixed income and collaterized loan obligations, or CLOs. The company has earned more than $3 billion using its expert investment strategies.

Part of the philosophy of the company is the belief that successful investing is a team effort, and that it requires curious minds that are open to seeing different points of view. Its CEO, Steve Wishnia, has been a part of the financial industry for more than 45 years. He received his business degree from Pace University in New York City, and was also one of Highland Capital’s founding members.

The firm focuses on trying to develop long-term relationships with their clients by involving them in the investment process. They also provide their clients the opportunity to learn about their investment strategies by offering them an online class in their Trading Academy. Additionally, Highland Capital mentors help aspiring entrepreneurs by giving them advice and providing them with more learning opportunities.

All of the company’s leaders have decades of experience in the field of finance. Co-founder James Dondero, who is the president and Chartered Financial Analyst, or CFA, of Highland Capital Management, has been involved in the equity and credit markets for over 30 years. And the other CFA and founder of the organization, Mark Okada, also has more than 30 years of experience, with a specialization in the categories of credit and alternative investing.

The business is based in Dallas, Texas, and it has offices in other places in both the U.S.,as well as other countries. These places include New York, Sao Paulo, Brazil, and southeastern Asian cities, Singapore and Seoul. For more than two decades, the Registered Investment Advisor, or RIA, company has worked to maintain its high standards in the alternative investment market, with the belief that being a successful investor takes time and dedication.